Sino Meir

SinoMeir is a Chinese biopharmaceutical company specializing in the development and commercialization of long-acting recombinant protein therapeutics. The company utilizes its proprietary PEGylation technology platform to enhance the therapeutic efficacy and pharmacokinetic profiles of biologics. Its lead product, Sinopeg (PEG-rhG-CSF), is a long-acting granulocyte colony-stimulating factor used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. Beyond oncology, SinoMeir is advancing a pipeline of long-acting proteins for growth hormone deficiency and infectious diseases. The company maintains integrated research, development, and GMP-compliant manufacturing capabilities in Beijing. SinoMeir aims to improve patient compliance and clinical outcomes by reducing the frequency of administration for essential biologic treatments.